EARNINGS PER SHARE

6 Months Ended

Jun. 30, 2023

On January 3, 2023, there were approximately 454 million shares of GE HealthCare common stock outstanding, including the interest in our outstanding shares of common stock retained by GE following the Distribution. The computation of basic and diluted earnings per common share for all periods through December 31, 2022 was calculated using this same number of common shares outstanding since no GE HealthCare equity awards were outstanding as of the Distribution Date and is net of Net (income) loss attributable to noncontrolling interest which is fully associated with continuing operations.


Earnings Per Share
	For the three months ended June 30				For the six months ended June 30
(In millions, except per share amounts)	2023		2022		2023		2022
Numerator:
Net income from continuing operations	$	433	$	486	$	816	$	888
Net (income) attributable to noncontrolling interests	(15)		(13)		(26)		(26)
Net income from continuing operations attributable to GE HealthCare	418		473		790		862
Deemed preferred stock dividend of redeemable noncontrolling interest	—		—		(183)		—
Net income from continuing operations attributable to GE HealthCare common shareholders	418		473		607		862
Income from discontinued operations, net of taxes	—		12		—		12
Net income attributable to GE HealthCare common stockholders	$	418	$	485	$	607	$	874
Denominator:
Basic weighted-average shares outstanding	455		454		455		454
Dilutive effect of common stock equivalents	3		—		3		—
Diluted weighted-average shares outstanding	458		454		458		454
Basic Earnings Per Share:
Continuing operations	$	0.92	$	1.04	$	1.34	$	1.90
Discontinued operations	—		0.03		—		0.03
Attributable to GE HealthCare common stockholders	0.92		1.07		1.34		1.93
Diluted Earnings Per Share:
Continuing operations	$	0.91	$	1.04	$	1.33	$	1.90
Discontinued operations	—		0.03		—		0.03
Attributable to GE HealthCare common stockholders	0.91		1.07		1.33		1.93
Antidilutive securities(a)	4		—		4		—

(a) Diluted earnings per share excludes certain shares issuable under share-based compensation plans because the effect would have been antidilutive.